Publications by authors named "Jan A Hillert"
Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
January 2025
Background And Objectives: While obesity is a known risk factor of the development of multiple sclerosis (MS), its impact on MS disease progression remains unclear. We aimed to investigate the influence of body mass index (BMI) on disease activity and progression, cognitive performance, and health-related quality of life in patients with MS.
Methods: Patients from an incident population-based case-control study (n = 3,249) were categorized based on BMI status at diagnosis and followed up after diagnosis through the Swedish MS registry.
Association Between Alcohol Consumption and Disability Accumulation in Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
September 2024
Article Synopsis
- This study investigates the impact of alcohol consumption on disease progression and quality of life in patients with multiple sclerosis (MS), following a large group over 15 years.
- Results indicate that low to moderate alcohol consumption is linked to a reduced risk of worsening disability, especially in women and those with relapsing-remitting MS, while high alcohol consumption showed no significant effects.
- Researchers found that the beneficial effects of low to moderate drinking were more pronounced among patients who maintained their drinking habits over the study period, suggesting a consistent drinking pattern may contribute to better outcomes.
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
Neurol Neuroimmunol Neuroinflamm
November 2022
Background And Objectives: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed.
Methods: Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19).
Background And Objectives: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS.
Methods: Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries).